Jean-Loup LemesreD. AfchainOscar OrozcoM. LoyensSimone Frédérique BrénièreP. DesjeuxY CarlierUbaldo O. MartínJ. A. Nogueira-QueirozD. Le Ray2026-03-222026-03-22198610.4269/ajtmh.1986.35.86https://doi.org/10.4269/ajtmh.1986.35.86https://andeanlibrary.org/handle/123456789/49726Citaciones: 22Coexistence of Chagas' disease with leishmaniasis and T. rangeli infection in endemic areas and cross-reactivity between corresponding etiological agents can confuse the immunodiagnosis of Chagas' disease. A discriminative serological test could therefore represent a major advance in specific immunodiagnosis. A competitive antibody enzyme immunoassay against a component 5-enriched preparation, using a T. cruzi species-specific monoclonal antibody has allowed development of a specific serodiagnosis of Chagas' disease with high sensitivity (96.6% in undetermined and chronic phases of infection). This test can differentiate Chagas' disease from other cross-reacting parasitic diseases in areas where concomitant infections are unknown or suspected.enTrypanosoma cruziChagas diseaseImmunoassayMonoclonal antibodyAntibodyTrypanosomiasisBiologyVirologyImmunologyarticle